-
Mobilizing the Immune System
A clinical-stage biopharmaceutical company leveraging from its multiple drug development platforms to treat patients with inflammatory diseases, viral infections, and cancer. -
ABX464
Fighting Inflammatory Diseases
Abivax’s lead candidate ABX464, a potent anti-inflammatory agent, is entering a Phase 2b clinical trial for its potential to bring clinical benefit to patients with ulcerative colitis, and potentially other inflammatory indications. -
ABX464
Developing a Functional Cure for HIV
ABX464 is a Phase 2 candidate designed to functionally cure HIV by reducing the viral reservoir and is the first ever drug candidate to demonstrate this reduction in patients. -
ABX196
Tackling Cancer
A small molecule agonist of invariant Natural Killer T-Cells (iNKT) to be tested in Phase 1/2 clinical trial for treatment of hepatocellular carcinoma (HCC).
About Us
Abivax is developing therapies that stimulate the body’s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat ulcerative colitis, HIV, and liver cancer.
Its lead clinical candidate, ABX464, has demonstrated the potential to address indications in two disease areas: treatment of inflammation in ulcerative colitis and reduction of the viral reservoir in HIV.
Learn More View our Corporate Presentation
Abivax recently presented impressive results from its ABX464 maintenance study in ulcerative colitis at the United European Gastroenterology Conference, UEG Week 2019, in Barcelona, Spain on October 21, 2019. This data showed that impressive efficacy initially reported at 8 weeks after completion of the induction study is durable or improving at 12 months with ABX464. You can see documentation from these presentations here:
Abivax recently presented impressive 9-month interim extension data from studies of ABX464 in ulcerative colitis during an oral presentation at DDW 2019, demonstrating a continued duration of beneficial effect in patients treated up to 11 months with ABX464 (for patients who received ABX464 during the placebo controlled 8 weeks induction study). View the conference presentation, here:
View Presentation Presentation Audio
On Thursday March 21, 2019, Abivax hosted a webcast of their KOL lunch, in which Prof. Ian McGowan, MB ChB DPhil MD FRCP, from the University of Miami Miller School of Medicine discussed Abivax’s recently presented results from its Phase 2a extension study of ABX464 in ulcerative colitis. A recording of the webcast can be accessed via the following link:
Pipeline
With three products in clinical trials and four products in Research and Preclinical development, Abivax’s pipeline is strong and diversified, addressing many unmet needs.
Clinical Programs
-
ABX464 UC
ABX464 is an oral, first-in-class small molecule that has demonstrated anti-inflammatory activity in preclinical trials and shown impressive clinical safety and efficacy results in a Phase 2a proof of concept and in a Phase 2a 12-month maintenance study in patients with ulcerative colitis.
Read More -
ABX464 HIV
ABX464 is an oral, first-in-class, novel, small molecule inhibiting HIV replication through an entirely new mechanism of action. For the first time in the treatment of HIV, this molecule could reduce or eliminate the viral reservoirs, and thus potentially deliver a long-lasting virological suppression in HIV-patients.
Read More -
ABX464 Crohn’s Disease
-
ABX464 Rheumatoid Arthritis
-
ABX196 HCC
ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies cells with immune enhancing potential in cancer models.
Read More
R&D Assets
Science
Based on innovative research driven by the idea of stimulating the body’s natural immune system mechanisms to cure diseases.
Investors
Abivax SA has been listed on the Paris stock exchange since June 26, 2015.
Symbol
ABVX
